Advertisement
Canada markets closed
  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • DOW

    38,675.68
    +450.02 (+1.18%)
     
  • CAD/USD

    0.7308
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     
  • Bitcoin CAD

    86,154.98
    +5,030.02 (+6.20%)
     
  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     
  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     
  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     
  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics

Amedisys (AMED) reported $571.41 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 2.7%. EPS of $1.03 for the same period compares to $1.00 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $564.58 million, representing a surprise of +1.21%. The company delivered an EPS surprise of +1.98%, with the consensus EPS estimate being $1.01.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Amedisys performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Service Revenue- Home health: $364 million versus the two-analyst average estimate of $358.15 million. The reported number represents a year-over-year change of +6%.

  • Net Service Revenue- High Acuity Care: $6.40 million versus $6.20 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +36.2% change.

  • Net Service Revenue- Hospice: $201 million versus the two-analyst average estimate of $202.55 million. The reported number represents a year-over-year change of +3.9%.

View all Key Company Metrics for Amedisys here>>>

Shares of Amedisys have returned -1.2% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amedisys, Inc. (AMED) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research